Pressure for increased transparency in pharma can create antitrust risks, says Novartis counsel
Credit: Andrew from Flickr
The wealth of information available about pharmaceutical prices presents antitrust risks in the current political environment, a Novartis in-house lawyer said yesterday.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10